港股異動 | 微盟(2013.HK)大漲31% WOS新商業操作系統正式公測 於本月底放榜
格隆匯3月16日丨微盟集團(2013.HK)大幅反彈31%,報3.76港元,成交額放大至3.8億港元,總市值96億港元。今日,微盟WOS新商業操作系統正式開啟公測。據悉,作為中國企業服務領域,首個面向去中心化時代的商業操作系統,微盟WOS系統旨在為未來的智慧商業提供一整套可快速迭代的基礎設施,從而在數字經濟背景下,幫助企業通過去中心化經營實現可持續增長。另外,公司將於3月28日舉行董事會會議以審批年度業績,此前中期業績顯示營收同比增長44.5%至13.83億元,SaaS收入倍增至9.59億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.